Pharma M&A Impact on CRO CDMO Contracts: When Your Client Gets Acquired

Q: How long after an acquisition do vendor decisions get made?

Program-level decisions often land within 3 to 6 months after close. Supplier rationalization decisions usually follow in months 6 to 18, once integration teams have consolidated spend data across both legacy organizations and identified duplicate suppliers.

Q: What are the earliest signs a client is about to be acquired?

Look for clusters of signals: lengthening decision cycles on routine approvals, a freeze on new program starts, unexpected CFO or corporate development involvement, requests for detailed historical documentation as diligence preparation, and a strong clinical readout followed by advisor appointments.

Imen Jelassi

2 days ago

10 min read

Key Takeaways

The wave is structural, not cyclical. Over $230 billion of biopharma revenue faces loss of exclusivity by 2030, and another $200 to $250 billion in the early 2030s, which is why acquisition volume is running at record levels rather than settling down (IQVIA).
Acquisition does not kill your contract, the portfolio review does. Biogen paused or discontinued most of Apellis' legacy research portfolio roughly three months after a $5.6 billion deal. The programs you support get re-ranked before anyone reviews your SOW.
Procurement rationalization is the second hit. Post-merger integration playbooks target supplier overlap in the first 90 days, so two vendors doing the same work across the two legacy companies become one.
The signals are visible 6 to 12 months early. Slowed decision cycles, a freeze on new program starts, sudden CFO involvement in mid-size approvals, and your champion quietly interviewing elsewhere are all readable before the press release.
The defensible position is platform, not project. Vendors contracted at the enterprise level (MSA, multi-program, named on the approved vendor list) survive integration far more often than vendors attached to a single study or a single molecule.

The email you do not want to read on a Tuesday

It usually arrives as good news. Your client, a mid-size biotech you have supported for two years, announces it is being acquired by a top-20 pharma company. Your champion sends a short, upbeat note. Everyone congratulates each other.

Six months later your purchase orders stop.

This is the most under-managed revenue risk in life sciences services. CROs and CDMOs build sophisticated processes for winning new clients and almost none for keeping the ones that change owner. Yet in a market where biopharma M&A reached roughly $130 billion across the first half of 2026 alone, and where average deal size climbed to about $3.1 billion, the odds that at least one meaningful account gets acquired in any given year are no longer small (IQVIA mid-year 2026 update).

The pharma M&A impact on CRO CDMO contracts is not evenly distributed. Some vendors lose the account within two quarters. Others end up with three times the revenue because the acquirer needed exactly their capability and they were already qualified. The difference is rarely the quality of the science. It is whether the vendor saw it coming and had a plan for the first 90 days after close.

This article covers what actually happens to service contracts through an acquisition, the early warning signals, and the specific business development moves that protect and sometimes grow revenue.

Why the M&A wave is not slowing down

Understanding the driver helps you predict which clients are exposed.

The industry is facing a concentrated loss-of-exclusivity event. More than $230 billion of biopharma revenue is exposed to patent expiry by 2030, covering brands including Keytruda, Eliquis, Opdivo and Darzalex, with a further $200 to $250 billion exposed in the early 2030s (IQVIA). Large pharma cannot close a gap of that size organically inside a decade, so it buys late-stage, de-risked assets instead.

The numbers follow. Aggregate biopharma M&A value rose about 133% in 2025 to roughly $133 billion, and 2026 is tracking well ahead of forecast, with some trackers putting the running total at roughly $106 billion across 201 transactions and a plausible full-year outcome above $200 billion (IQVIA, Life Science Daily).

For a service provider, the practical read is this: your most attractive clients are the most likely to be acquired. A clinical-stage biotech with strong Phase 2 data in oncology, immunology, obesity or rare disease is precisely the profile being bought. Concentrating your pipeline on that profile is good commercial strategy and a concentrated risk at the same time.

Worth noting: the buy-side is not the only source of turbulence. Your own market is consolidating too. Charles River announced in early 2026 it would divest its European Discovery Services, CDMO and Cell Solutions businesses, and Worldwide Clinical Trials agreed to acquire Catalyst Clinical Research. Sponsors now routinely ask vendors for contingency plans in case the vendor itself restructures.

Pharma M&A Impact on CRO CDMO Contracts: What Happens After Close

Contracts rarely get cancelled on day one. Legal continuity provisions usually carry existing agreements over to the acquiring entity. The damage comes later, in three predictable waves.

Wave 1: the portfolio review (months 1 to 6)

The acquirer re-ranks every program against its own strategic priorities. Programs that were the acquired company's top asset can become the acquirer's fourth priority overnight.

This is not theoretical. Biogen began scaling back much of the research pipeline it acquired through its $5.6 billion purchase of Apellis roughly three months after the takeover, pausing or discontinuing funding across most of the legacy research portfolio while it reviewed the clinical and preclinical assets. Pfizer dropped two Seagen antibody-drug conjugates as part of a group of eleven discontinuations after its $43 billion acquisition.

If your revenue sits on a program that gets deprioritized, no amount of relationship strength saves the contract. The work simply stops existing.

Wave 2: procurement rationalization (months 6 to 18)

The integration team looks for cost synergies, and procurement is where they are found fastest. Standard post-merger integration practice is to consolidate spend data, identify supplier overlap and rationalize duplicate vendors inside the first 90 days of integration planning, then negotiate improved terms with a reduced, strategically selected supplier base.

In practice, if the acquirer already works with a CDMO that does sterile fill-finish and you were the acquired company's sterile fill-finish partner, one of you is being consolidated out. The decision is often made on enterprise spend leverage and existing qualification status, not on your performance scorecard for one program.

Wave 3: relationship loss (continuous)

Your champion leaves. Biopharma eliminated roughly 42,700 roles in 2025, a 47% increase on the prior year, and acquired-company commercial and R&D operations staff are disproportionately affected. The person who understood why you were chosen and what you fixed in year one is gone, and the institutional memory of your value goes with them.

The early warning signals

You can usually read an acquisition 6 to 12 months before it is public. Watch for clusters, not single signals.

Commercial signals

Decision cycles suddenly lengthen on routine approvals that used to take a week
A freeze on new program starts while existing work continues normally
The CFO or a corporate development contact appears in conversations that never used to involve them
Multi-year commitments get replaced with quarter-by-quarter extensions
Requests for unusually detailed documentation of work performed, which is diligence preparation

Public signals

Advisors appointed, banker hires, or a strategic review announced
Positive Phase 2 or Phase 3 readout in a hot therapeutic area
Cash runway approaching 12 to 18 months with no financing announced
Founder or CEO change, or a new chief business officer hire
Unusual trading volume for a listed client

People signals

Your champion updates their LinkedIn profile or goes quiet
Hiring freezes on the client's careers page
Key scientific staff start speaking at conferences about "next chapter" themes

Set up alerts on every top-20 account. This is the same trigger-based monitoring discipline described in our guide to selling to newly funded biotech, pointed at a different event.

Three positions to hold before the deal closes

Most defensive work has to be done before the announcement. Once integration starts, you are negotiating from a weaker position with people who do not know you.

1. Contract at the platform level, not the project level

A vendor attached to one study or one molecule is a line item. A vendor with a signed master service agreement covering multiple programs, a quality agreement in place, and a completed audit is an infrastructure decision that costs money to unwind.

Make it explicit in your renewals. Push for a multi-program MSA even when only one program is active. Get the quality agreement executed. Complete the audit, even if it feels premature. Those documents travel to the acquirer and they are the cheapest insurance available.

2. Multi-thread the relationship

Single-threaded accounts do not survive acquisitions. Map and build relationships across at least four roles: the scientific sponsor, the program or project manager, procurement or outsourcing, and quality. Each of these has a counterpart at the acquirer, and each counterpart is a potential advocate during integration.

This is the same principle covered in our pipeline optimization guide, applied to retention rather than acquisition.

3. Document value in the acquirer's language

Keep a running one-page account record: cycle times achieved, deviations avoided, tech transfer completed on schedule, batches released, audit findings closed. When integration starts, your advocate inside the client needs something they can forward. A warm feeling about your team is not forwardable. A page of delivery metrics is.

The first 90 days after the announcement

The window between announcement and close is when vendors either get on the acquirer's radar or disappear.

Days 1 to 14. Call your champion, congratulate them, and ask two questions: who is leading integration for R&D or manufacturing, and what happens to the programs you support. Do not pitch. Gather intelligence.

Days 15 to 45. Map the acquirer. Identify whether they already have a preferred vendor in your category, who owns outsourcing decisions, and whether they run a formal approved vendor list. Find out if you are already qualified with them anywhere in the organization, which is more common than people expect in mid-size CROs and CDMOs.

Days 45 to 90. Ask your champion for a warm introduction to the acquirer's equivalent function, framed around continuity of the program rather than around your company. "I want to make sure the tech transfer timeline is understood by whoever picks this up" is a request that gets granted. "I would like to introduce our capabilities" is a request that gets ignored.

After close. Treat the acquirer as a new business development target with a qualification head start. Your goal is to move from inherited vendor to selected vendor, which usually means getting onto their approved vendor list. The criteria the acquirer will score you against are the same sponsor scorecard covered in our CDMO selection criteria article, and if a formal bid follows, our guide to responding to a CDMO or CRO RFP covers the submission itself.

Which vendors survive integration: a comparison

Factor	Vendor likely to be cut	Vendor likely to be retained	Vendor likely to expand
Contract structure	Single project SOW, no MSA	Multi-program MSA, quality agreement signed	Enterprise MSA plus approved vendor list status at the acquirer
Relationship depth	One champion, one function	Three to four contacts across science, PM, procurement	Relationships at both legacy companies before the deal
Capability overlap	Duplicates an incumbent at the acquirer	Complementary or specialist capability	Fills a capacity or modality gap the acquirer has
Program exposure	Tied to one asset, non-core to acquirer	Spread across two or more programs	Supports an asset central to the deal thesis
Switching cost	Low, work is commoditized	Medium, tech transfer required	High, regulatory filings name the site
Documented value	Anecdotal, lives with the champion	Quarterly metrics shared in writing	Metrics plus a documented audit and inspection record
Typical outcome	Wind-down at next renewal	Contract continues, scope flat	Scope grows across the combined portfolio

The pattern across the table is consistent. Survival is a function of how expensive you are to remove and how visible your value is to someone who has never met you.

The offensive play: acquisitions create demand too

Retention is the defensive half. The other half is that every acquisition creates a buyer with new problems.

An acquirer that just bought a clinical-stage asset needs capacity it did not plan for, often at a modality it does not manufacture in-house. Integration creates tech transfer work, comparability studies, second-source qualification and, frequently, an urgent need for a partner who already knows the acquired program. That last point is the strongest position a service provider can hold, because institutional knowledge of a program under integration pressure is genuinely scarce.

Build a target list of recent acquirers in your capability area and approach them on that basis. The message is specific: we ran this process for the acquired entity, here is the timeline risk in transferring it, and here is how we de-risk it. That is a problem-led opening rather than a capabilities pitch, which is the distinction we covered in inbound versus outbound in life sciences.

The same logic applies to divestitures. When a large provider sheds a business unit, its clients become available. Charles River's 2026 divestitures, for example, put a set of European discovery and CDMO relationships into motion.

Building this into normal BD practice

None of the above works as a one-off reaction. It works as a quarterly routine:

Concentration review. What percentage of revenue sits with your top three clients, and which of them fit the acquisition profile? Anything above 40% in a single acquirable account is a board-level risk.
Signal scan. Review the warning list above against your top 20 accounts. Fifteen minutes per account, once a quarter.
Contract audit. Which active clients have no MSA, no quality agreement, or no completed audit? Fix in order of revenue at risk.
Thread count. Which accounts have fewer than three named contacts? Those are your fragile accounts regardless of how good the relationship feels.
Acquirer target list. Which companies bought a relevant asset in the last 12 months, and are they on your outbound list?

For smaller CROs and CDMOs without a dedicated account management layer, this is a realistic candidate for fractional support, since it is high-value work that does not require a full-time head. We cover that trade-off in fractional business development versus hiring a BD manager and in the fractional BD model overview.

Frequently asked questions

Does a pharma acquisition automatically cancel a CRO or CDMO contract? No. Existing agreements usually transfer to the acquiring entity under standard assignment provisions. The risk comes later, from the portfolio review that deprioritizes specific programs and from procurement rationalization that removes duplicate suppliers, typically in the first 6 to 18 months after close.

How long after an acquisition do vendor decisions get made? Program-level decisions often land within 3 to 6 months, as the Biogen and Apellis case illustrated. Supplier rationalization decisions usually follow in months 6 to 18, once integration teams have consolidated spend data across both legacy organizations.

What are the earliest signs a client is about to be acquired? Look for clusters: lengthening decision cycles on routine approvals, a freeze on new program starts, unexpected CFO or corporate development involvement, requests for detailed historical documentation (diligence preparation), and a strong clinical readout followed by advisor appointments.

How can a small CRO or CDMO protect revenue when a client is acquired? Contract at the platform level rather than the project level, so an MSA, quality agreement and completed audit are already in place. Multi-thread relationships across science, project management, procurement and quality. Keep written delivery metrics your champion can forward to the acquirer. Then treat the acquirer as a business development target and pursue approved vendor list status.

Is an acquisition ever good news for a service provider? Yes, frequently. Acquirers face unplanned tech transfer, comparability and capacity needs, and they value partners who already know the acquired program. Vendors who move early and reposition from project supplier to platform partner often end up with more scope across the combined portfolio than they had before.

Work with Corstrate

Corstrate is a boutique business development consultancy for life sciences service providers across the US and EU. We help CROs, CDMOs and specialist vendors build pipeline that does not depend on a single account surviving its next corporate event. If a key client is in play, or you want a concentration review of your top accounts, get in touch.